Reducing Cholesterol with β-CDP: Insights for NPC and AD
Niemann–Pick disease type C (NPC) and Alzheimer’s disease (AD) are neurodegenerative disorders characterised by cognitive dysfunction and neurological impairment. In
Tag: Niemann-Pick disease type C
Beren Therapeutics’Adrabetadex Received FDA Acceptance for infantile-onset Niemann Pick Disease
Beren Therapeutics Announced FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann-Pick Disease Type C. Beren Therapeutics
JIC Venture Growth Investments Invests in Beren Therapeutics P.B.C. to Advance Innovative, Cyclodextrin-based Therapeutics
JIC Venture Growth Investments (VGI) announced that it has invested in Beren Therapeutics P.B.C. (“Beren Therapeutics”). Beren Therapeutics is developing
7 of 9 patients showed stabilization or improvement: preliminary data from ongoing Phase 3 TransportNPC™ clinical trial
Rafael Holdings, Inc. announced that data from Cyclo Therapeutics’ Phase 3 TransportNPC™ open-label, single-arm sub-study evaluating Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick
Rafael Holdings and Cyclo Therapeutics merge to advance Niemann-Pick drug as FDA rival decision nears
Rafael Holdings and Cyclo Therapeutics on Thursday announced a merger agreement as they look to spur development of their Niemann-Pick
Cyclodextrins as therapeutic drugs for treating lipid metabolism disorders
This study sought to systematically compare the efficacy and mechanism of cyclodextrins as drug interventions in lipid metabolism diseases, potentially
Alterations in Proteostasis Mechanisms in Niemann–Pick Type C Disease
Niemann–Pick Type C (NPC) represents an autosomal recessive disorder with an incidence rate of 1 in 150,000 live births, classified
Merger of Cyclo Therapeutics and Applied Molecular Transport
Cyclo Therapeutics, (Cyclo) a clinical stage company focused on developing therapies for rare and neurological diseases with limited treatment options,
Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases
This work presents the most recent advances in the research and clinical use of HPβCD against Niemann–Pick disease, a congenital
The background story on how the HPBCD became and orphan drug (Hommage’ a Families, Parents)
The Pulitzer Prize-winning Wall Street Journal science- and health writer, Amy Dockser Marcus, in her new book „We the Scientists”